I'd like to hear @Owl vs Fox and @DoctorBrad thoughts on this development. How common is it that a patient remains on the treatment post Phase 3 trial? This is undoubtedly a good thing
Ann: First patient enters into Open Label Extension study, page-43
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
48.0¢ |
Change
0.035(7.87%) |
Mkt cap ! $275.7M | |||
| Open | High | Low | Value | Volume |
| 45.5¢ | 49.5¢ | 45.0¢ | $1.184M | 2.466M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 8515 | 48.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 48.5¢ | 79159 | 4 |
View Market Depth
| Last trade - 11.05am 14/10/2024 (20 minute delay) ? |
| DXB (ASX) Chart |